Quantcast
Viewing all articles
Browse latest Browse all 484

Oncothyreon losses widen in Q1

Image may be NSFW.
Clik here to view.
Oncothyreon Inc.’s net losses widened in the first quarter of 2013, a change the company largely attributes to administrative expenses and an increase in research and development. The Seattle-based biotech reported first-quarter operations losses of $8 million Thursday, compared with $5.7 million for the same period in 2012. Oncothyreon’s R&D expenses for Q1 2013 increased to $5.8 million from $4.3 million in the first quarter of 2012. During that same period, administrative expenses rose…

Viewing all articles
Browse latest Browse all 484

Trending Articles